Massimiliano Bonifacio

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 845 citations · Full text

Medicine, Hematology, Oncology +13

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Robin Foà, Renato Bassan, Antonella Vitale et al. · New England Journal of Medicine · 2020 · 499 citations · Full text

Medicine, Hematology, Oncology +12

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 149 citations · Full text

Medicine, Hematology, Pharmacology +10

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Robin Foà, Renato Bassan, Loredana Elia et al. · Journal of Clinical Oncology · 2023 · 145 citations · Full text

Medicine, Oncology, Pharmacotherapy +14